On 5 June 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE) held its 2025 Annual General Meeting in Beijing. Shareholders representing 76.81 million H shares, or 45.04 % of the issued share capital, voted by poll on 13 resolutions. All items gained the required majorities and are now effective.

Key ordinary resolutions • 2025 Annual Report: 99.74 % approval. • 2025 profit distribution plan and 2026 directors’ remuneration plan: each passed with 97.58 % support. • Re-appointment of Ernst & Young as external auditor and amendments to Corporate Governance Rules: both secured 97.58 % approval.

Key special resolutions • H Share Option Scheme, H Share Incentive Scheme, Scheme Limit and Service Provider Sublimit each passed with 84.46 % support. • Authorisation for the board to handle matters related to the H Share schemes gained 86.17 % approval. • Cancellation of the Supervisory Committee and related amendments to the Articles of Association achieved 96.85 % support. • General mandates to issue shares and to repurchase H shares received 87.67 % and 96.85 % approval respectively.

Articles of Association updated Following shareholder consent, the revised Articles of Association became effective immediately on 5 June 2026.

Computershare Hong Kong Investor Services Limited acted as scrutineer for the vote-taking process. All directors attended the meeting, chaired by Board Chairman Dr. Liang Zicai.